Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07136142) titled 'A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors' on Aug. 14.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Condition:
Malignant Solid Tumor
Intervention:
Drug: FH-006 for Injection
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: August 2025
Target Sample Size: 150
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT0713614...